NCT04876651 trial: what clinicians have said so far
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
- NCT04876651 ↗
- Terminated
- Telix Pharmaceuticals (Innovations) Pty Ltd
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT04876651 (PSMA-expressing metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 9 indexed sources
Automated from all 9 indexed sources (Jan 2022 – Jun 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether adding 177Lu-rosopatamab to an ARPI or docetaxel improves on that standard of care alone
- Whether 177Lu-rosopatamab in ProstACT offers more than 177Lu-PSMA-617, and how the two would be sequenced
- Whether 177Lu-rosopatamab spares salivary glands and kidneys, and what its liver uptake means for safety
Indexed commentary on NCT04876651 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X, typically up to 26 once built | |
| 2 YouTube videos, typically up to 9 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Metastatic Prostate Cancer
- Interventions
- 177Lu-DOTA-rosopatamb; Standard of Care
- Arms
- Group A · Experimental
- Group B · Active comparator
- Biodistribution and Dosimetry Sub-Study · Experimental
- Enrollment
- 16
- Primary outcomes
- Comparison of radiographic progression-free survival (rPFS)
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
- Start
- Aug 29, 2023
- Primary completion
- Jul 1, 2025
- Results posted
- No
- Registry record
- NCT04876651 · updated Feb 20, 2026